Breaking News, Collaborations & Alliances

Dalton, ExCellThera in Devt. and Mfg. Pact

Dalton will be responsible for the formulation and fill/finish of ExCellThera's lead candidate UM171

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Dalton Pharma Services has entered a drug development and manufacturing services agreement with ExCellThera Inc, a biotechnology company focused on molecules and bioengineering solutions to expand stem and immune cells for therapeutic use. ExCellThera will have access to Dalton`s cGMP biopharmaceutical facility in Toronto, ON. Dalton will be responsible for the formulation and fill/finish of UM171, a constituent of ExCellThera’s lead technology, ECT-001, to support Phase II trials in Ca...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters